The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention.

[1]  E. Walsh,et al.  Respiratory Syncytial Virus Infection in Adults , 2000, Clinical Microbiology Reviews.

[2]  H. Rosenberg,et al.  Animal Models for Studying Respiratory Syncytial Virus Infection and Its Long Term Effects on Lung Function , 2004, The Pediatric infectious disease journal.

[3]  H. Rosenberg,et al.  Functional Antagonism of Chemokine Receptor CCR1 Reduces Mortality in Acute Pneumovirus Infection In Vivo , 2004, Journal of Virology.

[4]  Erik De Clercq,et al.  Antiviral drugs in current clinical use. , 2004 .

[5]  S. Barik,et al.  New drugs and treatment for respiratory syncytial virus , 2004, Reviews in medical virology.

[6]  H. Rosenberg,et al.  Animal Pneumoviruses: Molecular Genetics and Pathogenesis , 2004, Clinical Microbiology Reviews.

[7]  T. Kimman,et al.  Respiratory syncytial virus, pneumonia virus of mice, and influenza A virus differently affect respiratory allergy in mice , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  J. Kimpen,et al.  Advances in respiratory syncytial virus vaccine development. , 2004, Current opinion in investigational drugs.

[9]  P. Ogra.  Respiratory syncytial virus: The virus, the disease and the immune response , 2004, Paediatric Respiratory Reviews.

[10]  R. Karron,et al.  The future of respiratory syncytial virus vaccine development , 2004, The Pediatric infectious disease journal.

[11]  R. Welliver.  Respiratory syncytial virus infection: therapy and prevention. , 2004, Paediatric respiratory reviews.

[12]  A. Greenough,et al.  Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity , 2003, Expert opinion on pharmacotherapy.

[13]  M. Siqueira,et al.  RESPIRATORY TRACT VIRAL INFECTIONS IN BONE MARROW TRANSPLANT PATIENTS , 2003, Transplantation.

[14]  L. To,et al.  An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment , 2003, Bone Marrow Transplantation.

[15]  C. Black.  Systematic review of the biology and medical management of respiratory syncytial virus infection. , 2003, Respiratory care.

[16]  J. Romero.  Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage , 2003, The Pediatric infectious disease journal.

[17]  H. Jafri.  Treatment of respiratory syncytial virus: antiviral therapies , 2003, The Pediatric infectious disease journal.

[18]  P. Piedra.  Clinical experience with respiratory syncytial virus vaccines , 2003, The Pediatric infectious disease journal.

[19]  H. Rosenberg,et al.  Altered Pathogenesis of Severe Pneumovirus Infection in Response to Combined Antiviral and Specific Immunomodulatory Agents , 2003, Journal of Virology.

[20]  L. D. Powell,et al.  The Quest for an Efficacious Antiviral for Respiratory Syncytial Virus , 2002, Antiviral chemistry & chemotherapy.

[21]  S. Niewiesk,et al.  Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases , 2002, Laboratory animals.

[22]  J. Friedland,et al.  Steroids Fail to Down-Regulate Respiratory Syncytial Virus-Induced IL-8 Secretion in Infants , 2002, Pediatric Research.

[23]  C. Cameron,et al.  Pleiotropic mechanisms of ribavirin antiviral activities. , 2002, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[24]  K. Dyer,et al.  Glucocorticoid administration accelerates mortality of pneumovirus-infected mice. , 2001, The Journal of infectious diseases.

[25]  Reyes Gr.  Ribavirin: recent insights into antiviral mechanisms of action. , 2001 .

[26]  R. Garofalo,et al.  Macrophage Inflammatory Protein-1α (Not T Helper Type 2 Cytokines) Is Associated with Severe Forms of Respiratory Syncytial Virus Bronchiolitis , 2001 .

[27]  D. Kwiatkowski,et al.  Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families , 2000, Thorax.

[28]  H. Rosenberg,et al.  The Chemokine Macrophage-Inflammatory Protein-1α and Its Receptor CCR1 Control Pulmonary Inflammation and Antiviral Host Defense in Paramyxovirus Infection , 2000, The Journal of Immunology.

[29]  R. Garofalo,et al.  Requirement of a Novel Upstream Response Element in Respiratory Syncytial Virus-Induced IL-8 Gene Expression1 , 2000, The Journal of Immunology.

[30]  Michelle M. Garrison,et al.  Systemic Corticosteroids in Infant Bronchiolitis: A Meta-analysis , 2000, Pediatrics.

[31]  K. Dyer,et al.  Pulmonary eosinophilia and production of MIP-1alpha are prominent responses to infection with pneumonia virus of mice. , 2000, Cellular immunology.

[32]  E. Simões.  Respiratory syncytial virus infection , 1999, The Lancet.

[33]  J. Stark,et al.  Mechanism of RSV-induced IL-8 gene expression in A549 cells before viral replication. , 1996, The American journal of physiology.

[34]  E. Wang,et al.  Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. , 1996, Archives of pediatrics & adolescent medicine.

[35]  R. Garofalo,et al.  Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. , 1992, The Journal of pediatrics.